Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Recruiting now · Phase 1

Conditions studied: Congenital Myasthenic Syndrome

In brief

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Key facts

Study ID

NCT07226726

Run by

The Foundation for Orthopaedics and Regenerative Medicine

People needed

20

Starts

2025-01-01

Expected to finish

2028-12-31

Last updated by the study team

2025-11-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
• Patients must be able to provide informed consent, or have a guardian who does.
• Patient must be able to travel to the site of treatment.

You may not qualify if…

• Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.

Where it is running

• Prodromos Stem Cell Institute — Naples, Florida, United States (enrolling)
• Prodromos Stem Cell Institute — Irving, Texas, United States (enrolling)
• Medical Surgical Associates Center — St John's, Antigua and Barbuda (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.